Mechanisms of Resistance to Chemotherapies Targeting BRCA-Mutant Breast Cancer
Technical Report,01 Dec 2014,30 Nov 2015
The Geneva Foundation Tacoma United States
Pagination or Media Count:
This research proposal for the BRCP Idea Expansion Award involves a detailed study of the underlying mechanisms of drug resistance in BRCA1 and BRCA2 deficient cells through the genetic manipulation of the major players that mediate homologous recombination and non-homologous end joining DNA repair pathways. These studies will serve as a foundational data set in determining the importance of DNA repair pathways in acquiring resistance to breast and ovarian cancer chemotherapies. Because drug resistance is an inescapable feature of all cancer treatments, an understanding of the causal mechanisms of resistance will undoubtedly provide new opportunities and susceptible targets in cancer therapies.